Fujian Guangshengtang Pharmaceutical Co., Ltd. announced that its innovative hepatitis B treatment drug, Neracorvir, has been added to the Breakthrough Therapy List, potentially accelerating its development. This inclusion recognizes the drug's significant clinical advantages and novel antiviral mechanism, distinguishing it from existing treatments.